Literature DB >> 25179989

[Posterior reversible encephalopathy syndrome (PRES) after kidney transplantation: a case report].

Norichika Ueda1, Masataka Kawamura1, Shigeaki Nakazawa1, Toshiaki Hirai1, Hidefumi Kishikawa1, Kenji Nishimura1.   

Abstract

A 60-year-old woman with chronic renal failure due to a polycystic kidney underwent living kidney transplantation. Initial immunosuppressive therapy consisted of tacrolimus (TAC), mycophenolate mofetil (MMF), prednisolone, and basiliximab. Furthermore, rituximab was administered, and double filtration plasmapheresis and plasma exchange were utilized because of ABO-incompatible transplantation, while intravenous immune serum globulin (IVIG) was given because donor specific antibody was positive. Four days after the renal transplantation, the patient developed visual abnormalities, a headache, and paralysis. Then, he became unconscious. Magnetic resonance imaging of the brain demonstrated bilateral posterior vasogenic edema. Our diagnosis was posterior reversible encephalopathy syndrome due to TAC neurotoxicity. After converting TAC to reduced cyclosporine and everolimus, the symptoms rapidly disappeared.

Entities:  

Mesh:

Year:  2014        PMID: 25179989

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  3 in total

1.  Late presentation of posterior reversible encephalopathy syndrome following liver transplantation in the setting of tacrolimus and cannabis use.

Authors:  Felix Zhou; Andreu F Costa; Magnus McLeod
Journal:  Can Liver J       Date:  2022-02-04

Review 2.  Posterior Reversible Encephalopathy Syndrome After Transplantation: a Review.

Authors:  Sheng Chen; Jun Hu; Liang Xu; Dixon Brandon; Jun Yu; Jianmin Zhang
Journal:  Mol Neurobiol       Date:  2015-12-14       Impact factor: 5.590

Review 3.  Calcineurin Inhibitors Associated Posterior Reversible Encephalopathy Syndrome in Solid Organ Transplantation: Report of 2 Cases and Literature Review.

Authors:  Turun Song; Zhengsheng Rao; Qiling Tan; Yang Qiu; Jinpeng Liu; Zhongli Huang; Xianding Wang; Tao Lin
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.